A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis
Status:
Completed
Trial end date:
2018-10-23
Target enrollment:
Participant gender:
Summary
This is a phase II study to determine the safety and preliminary efficacy of a human
monoclonal antibody (BTT1023) which targets the vascular adhesion protein (VAP-1) and its use
in the treatment of patients with primary sclerosing cholangitis (PSC).
Phase:
Phase 2
Details
Lead Sponsor:
University of Birmingham
Collaborators:
Biotie Therapies Corp. National Institute for Health Research, United Kingdom University Hospital Birmingham